<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974051</url>
  </required_header>
  <id_info>
    <org_study_id>07-0392</org_study_id>
    <nct_id>NCT00974051</nct_id>
  </id_info>
  <brief_title>Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia</brief_title>
  <official_title>The Effect of Using Terbutaline or a Reduction in Basal Insulin Infusion as a Therapeutic Agent to Prevent Delayed Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that the use of an oral dose of Terbutaline or a 20% basal
      reduction will be able to prevent nocturnal hypoglycemia after an afternoon exercise session.
      This is a randomized three period cross-over study including treatment with Terbutaline, a
      20% basal reduction for six hours, or no treatment (control).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, a minimum of 16 youth with type 1 diabetes will be recruited. All subjects
      must have been diagnosed with type 1 diabetes for at least one year and on an insulin pump
      for at least one month. Subjects are between the ages of 10 and 17 years, inclusive, have an
      HbA1c less than 10.0% and normal thyroid function. Subjects can not have had a severe
      hypoglycemic episode in the last three months, any other illness or treatment that may affect
      the wearing of a continuous glucose monitor or the completion of the study as determined by
      the investigator. Subjects may not use drugs containing pseudoephedrine within 48 hours of
      the study visits.

      This study consists of three overnight visits at the Clinical Translational Research Center.
      Meals eaten during the study will be consistent for each of the three visits.

      Subjects will participate in a standardized afternoon exercise session on a treadmill as has
      been done in previous Diabetes Research in Children Network studies. Exercise will begin at
      4pm and must be completed by 6pm. Dinner will be eaten at the end of the exercise.

      At 9pm, treatment will be given as determined by the randomization group the subject is
      assigned to. The treatment includes either an oral dose of 2.5mg Terbutaline, a 20% basal
      reduction for six hours or no treatment as the control. Blood glucose levels will be measured
      every 30 minutes until 6am.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Glucose Nadir</measure>
    <time_frame>overnight hours</time_frame>
    <description>BG nadir overnight after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Nighttime Glucose Levels &lt;80</measure>
    <time_frame>9:00pm to 6:00am</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Nighttime Glucose Levels &lt;70</measure>
    <time_frame>10:00pm to 6:00am</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Nighttime Glucose Levels &gt;250 mg/dl</measure>
    <time_frame>10:00pm to 6:00am</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects complete the same exercise routine, however no treatment is given at 9:00pm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Terbutaline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20% Basal Insulin Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for six hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbutaline</intervention_name>
    <description>Oral (2.5mg) one time administration at 9:00pm</description>
    <arm_group_label>Terbutaline</arm_group_label>
    <other_name>Î²2-adrenergic agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>20% basal insulin reduction</intervention_name>
    <description>Basal insulin rate is reduced by 20% the normal (home dose) for six hours.</description>
    <arm_group_label>20% Basal Insulin Reduction</arm_group_label>
    <other_name>80% basal insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No treatment is given for the study. This arm is for comparison with the two intervention arms.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>No intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Type 1 Diabetes and using daily insulin therapy for at least one
             year.

          -  Age 10 to 17 years, inclusive.

          -  HbA1c &lt; 10.0%.

          -  BMI 5-95th % for age and gender.

          -  Stable Continuous Subcutaneous Insulin Infusion regimen for at least 1 month and not
             anticipating a change prior to the subject's completion of the study.

          -  Subject uses a downloadable insulin pump.

          -  Normal thyroid function (measured within the previous year).

          -  For females, subject not intending to become pregnant during the study.

          -  No expectation that subject will be moving out of the area for the duration of the
             study.

          -  Informed consent form signed and understood by the parent/guardian and Child Assent
             form signed/understood by subjects.

        Exclusion Criteria:

          -  The presence of a significant medical disorder (including epilepsy, or any cause of
             seizures other than hypoglycemia) that in the judgment of the investigator will affect
             the wearing of the sensors or the completion of any aspect of the protocol.

          -  A recent injury to body or limb, Addison's disease, muscular disorder or disease in
             the judgment of the investigator that will affect the completion of the exercise
             protocol.

          -  Asthma which has been medically treated within the last year.

          -  Medically diagnosed cardiac disease, hypertension, or autonomic dysfunction.

          -  Use of pseudoephedrine 48 hours prior to the visit (if used in the 48 hours prior to
             the scheduled visit, the visit will be deferred)

          -  Severe hypoglycemia resulting in seizure of loss of consciousness in the 3 months
             prior to a visit.

          -  Active infection (if at the time of the scheduled visit and infection is present, the
             visit will be deferred).

          -  Anticipating a significant change in exercise regimen between visits (i.e. starting or
             stopping an organized sport).

          -  Treatment with systemic or inhaled corticosteroids in the last 6 months.

          -  Current treatment with B-blockers or presenting with high blood pressure.

          -  Inpatient psychiatric treatment in the past 6 months for either the subject or the
             subject's primary care giver.

          -  Current use of oral/inhaled glucocorticoids or other medications, which in the
             judgment of the investigator would be a contraindication to participation in the study

          -  Known allergy to Terbutaline

          -  Treatment with atenolol (Tenormin), carteolol (Cartrol), labetalol (Normodyne,
             Trandate), metoprolol (Lopressor), nadolol (Corgard), phenelzine (Nardil), propranolol
             (Inderal), sotalol (Betapace), theophylline (Theo-Dur), timolol (Blocadren),
             tranylcypromine (Parnate), other medications for asthma, heart disease or depression.

          -  Treatment with ephedrine, phenylephrine, phenylpropanolamine, or pseudoephedrine.

          -  The presence of an irregular heart beat, increased heart rate glaucoma or an
             overactive thyroid gland.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosanna Fiallo-Scharer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <results_first_submitted>September 17, 2012</results_first_submitted>
  <results_first_submitted_qc>August 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2013</results_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Exercise</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Adrenergic Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from the Barbara Davis Center pediatric population</recruitment_details>
      <pre_assignment_details>no notes</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control First, Then Terbutaline, Then 20% Basal Reduction</title>
          <description>Subjects complete the same exercise routine. No treatment is given during the Control night, Terbutaline is given at 9pm during the Terbutaline night, a 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night.</description>
        </group>
        <group group_id="P2">
          <title>Terbutaline First, Then 20% Basal Reduction, Then Control</title>
          <description>Subjects complete the same exercise routine. No treatment is given during the Control night, Terbutaline is given at 9pm during the Terbutaline night, a 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night.</description>
        </group>
        <group group_id="P3">
          <title>20% Basal Reduction First, Then Control, Then Terbutaline</title>
          <description>Subjects complete the same exercise routine. No treatment is given during the Control night, Terbutaline is given at 9pm during the Terbutaline night, a 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Subjects</title>
          <description>Subjects complete the same exercise routine. Subjects serve as there own control and participate in all interventions. No treatment is given during the Control night, Terbutaline is given at 9pm during the Terbutaline night, a 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Nighttime Glucose Levels &lt;80</title>
        <time_frame>9:00pm to 6:00am</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>No treatment is given during the Control night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Arm</title>
            <description>2.5 mg oral terbutaline is given at 9pm during the Terbutaline night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O3">
            <title>20% Basal Reduction Arm</title>
            <description>Subjects complete the same exercise routine. A 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Nighttime Glucose Levels &lt;80</title>
          <units>percentage of overnight glucose levels</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Nighttime Glucose Levels &lt;70</title>
        <time_frame>10:00pm to 6:00am</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>No treatment is given during the Control night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Arm</title>
            <description>2.5 mg oral terbutaline is given at 9pm during the Terbutaline night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O3">
            <title>20% Basal Reduction Arm</title>
            <description>Subjects complete the same exercise routine. A 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Nighttime Glucose Levels &lt;70</title>
          <units>percentage of nighttime glucose values</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Nighttime Glucose Levels &gt;250 mg/dl</title>
        <time_frame>10:00pm to 6:00am</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>No treatment is given during the Control night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Arm</title>
            <description>2.5 mg oral terbutaline is given at 9pm during the Terbutaline night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O3">
            <title>20% Basal Reduction Arm</title>
            <description>Subjects complete the same exercise routine. A 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Nighttime Glucose Levels &gt;250 mg/dl</title>
          <units>percentage of overnght glucose values</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="63.5"/>
                    <measurement group_id="O3" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Glucose Nadir</title>
        <description>BG nadir overnight after intervention</description>
        <time_frame>overnight hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Arm</title>
            <description>No treatment is given during the Control night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O2">
            <title>Terbutaline Arm</title>
            <description>2.5 mg oral terbutaline is given at 9pm during the Terbutaline night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
          <group group_id="O3">
            <title>20% Basal Reduction Arm</title>
            <description>Subjects complete the same exercise routine. A 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night. Glucose levels from 9 pm to 6 am are analyzed.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Nadir</title>
          <description>BG nadir overnight after intervention</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="58"/>
                    <measurement group_id="O2" value="189" spread="60"/>
                    <measurement group_id="O3" value="162" spread="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Subjects</title>
          <description>Subjects complete the same exercise routine. Subjects serve as there own control and participate in all interventions. No treatment is given during the Control night, Terbutaline is given at 9pm during the Terbutaline night, a 20% basal reduction is done starting at 9pm for six hours on the 20% basal reduction night.</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>during control intervention night</description>
        </group>
        <group group_id="E3">
          <title>Terbutaline Arm</title>
          <description>During turbutaline intervention night</description>
        </group>
        <group group_id="E4">
          <title>20% Basal Reduction Arm</title>
          <description>During 20% basal reduction night</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. H Peter Chase</name_or_title>
      <organization>UColorado</organization>
      <phone>303-724-2323</phone>
      <email>peter.chase@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

